ArticleJournal of clinical oncology : official journal of the American Society of Clinical Oncology2021
Clinicopathologic Features and Response to Therapy of
Abstract readMulticenter Study
In one paragraph
Article in Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers.
0numbers the graph read from it
0cells of the map it votes in
47citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
47 citing papers in PubMed.
- CRESTONE: A Phase II Study of the Efficacy and Safety of the HER3 Monoclonal Antibody, Seribantumab, in Solid Tumors With Neuregulin-1 (JCO precision oncology · 2025Trial
- Efficacy of Zenocutuzumab inThe New England journal of medicine · 2025Trial
- Trial
- Real-World Outcomes of Fusion-Directed Targeted Therapy in Advanced Non-Small Cell Lung Cancer Harboring Actionable Gene Fusions.International journal of molecular sciences · 2026Article
- NRG1 fusions in non-small cell lung cancer: biology, diagnostics, and emerging HER2/HER3 therapies-a narrative review.Translational lung cancer research · 2026Review
- Proactive identification of candidates for newly approved targeted therapies using a clinical decision support program.The oncologist · 2026Article
- NRG1 fusion-positive solid tumors: clinical detection, genomic landscape, and real-world data in pancreatic cancer.Journal of the National Cancer Institute · 2026Article
- Structure, mechanism and clinical relevance of NRG1 fusions in cancer.Journal of biomedical science · 2026Review
- European Society of Neuroendocrine Tumors (ENETS) 2025 guidance paper for lung and thymic carcinoids.Journal of neuroendocrinology · 2026Article
- Neoadjuvant afatinib in a patient with locally advanced lung adenocarcinoma harboring an NPTN-NRG1 fusion: a case report.World journal of surgical oncology · 2026Article
- Analysis of clinical and genomic features in a Chinese cohort withTranslational lung cancer research · 2026Article
- An evolving landscape: predictive and therapeutic biomarkers in advanced non-small cell lung cancer.Frontiers in oncology · 2026Review
- Review
- Comprehensive identification of NRG1 fusions in 25,203 patients with solid tumors.NPJ precision oncology · 2025Article
- HER3: Unmasking a twist in the tale of a previously unsuccessful therapeutic pursuit targeting a key cancer survival pathway.Genes & diseases · 2025Review
- Oncogenic Fusions in NSCLC: From Mechanisms to Clinical Applications.International journal of molecular sciences · 2025Review
- Oncogenic gene fusions in cancer: from biology to therapy.Signal transduction and targeted therapy · 2025Review
- NRG1 Fusions: The New Kid on the Block.Current oncology reports · 2025Review
- Bispecific antibody for lung cancer: mechanisms and clinical insights.Frontiers in immunology · 2025Review
- Young lung cancer: from diagnosis to survivorship.Frontiers in oncology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
36 authors.
Alexander DrilonMemorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY.ORCID 0000-0001-6806-9061
Michael DuruisseauxRespiratory Department, Louis Pradel Hospital, Hospices Civils de Lyon Cancer Institute, Lyon, France.
Ji-Youn HanNational Cancer Center, Korea, Goyang-si, South Korea.ORCID 0000-0001-5033-0006
Masaoki ItoPangaea Oncology, Quiron-Dexeus University Institute, Barcelona, Spain.
Christina FalconMemorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY.ORCID 0000-0001-9143-1639
Soo-Ryum YangMemorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY.
Yonina R Murciano-GoroffMemorial Sloan Kettering Cancer Center, New York, NY.
Haiquan ChenFudan University Shanghai Cancer Center, Shanghai Medical College, Fudan University, Shanghai, China.ORCID 0000-0001-7846-257X
Morihito OkadaResearch Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan.
Miguel Angel MolinaPangaea Oncology, Laboratory of Molecular Biology, Quiron-Dexeus University Institute, Barcelona, Spain.ORCID 0000-0001-8866-9881
Marie WislezUniversité de Paris, Centre de Recherche des Cordeliers, Sorbonne Université, INSERM, Paris, France.ORCID 0000-0001-7518-7859
Philippe BrunDepartment of Pneumology, Lungenklinik Heckeshorn, Helios Klinikum Emil von Behring, Valence, France.
Clarisse DupontRespiratory Department, Louis Pradel Hospital, Hospices Civils de Lyon Cancer Institute, Lyon, France.
Eva BrandenKarolinska Institute and Karolinska University Hospital Solna, Stockholm, Sweden.
Giulio RossiLocal Health Authority of Romagna, Infermi Hospital, Rimini, Italy.ORCID 0000-0001-8855-1218
Alexa SchrockFoundation Medicine Inc, Cambridge, MA.ORCID 0000-0003-0106-9096
Siraj AliFoundation Medicine Inc, Cambridge, MA.ORCID 0000-0001-7477-4023
Valérie GounantDepartment of Pulmonology, Hôpital Tenon, Assistance Publique Hôpitaux de Paris, Paris, France.ORCID 0000-0002-9473-1247
Fanny MagneHopital Nord Ouest Villefranche sur Saône, Gleizé, France.
Torsten Gerriet BlumDepartment of Pneumology, Klinikum Emil von Behring, Berlin, Germany.ORCID 0000-0003-1216-2157
Alison M SchramMemorial Sloan Kettering Cancer Center, New York, NY.ORCID 0000-0002-6070-2413
Isabelle MonnetCentre Hospitalier Intercommunal de Créteil, Créteil, France.
Jin-Yuan ShihNational Taiwan University Hospital and College of Medicine, National Taiwan University, Taipei, Taiwan.ORCID 0000-0002-2854-5067
Joshua SabariNew York University Langone Health Perlmutter Cancer Center, New York, NY.ORCID 0000-0002-1556-1543
Maurice PérolLéon Bérard Cancer Center, Lyon, France.ORCID 0000-0002-3296-423X
Viola W ZhuChao Family Comprehensive Cancer Center, Department of Medicine, Division of Hematology/Oncology, University of California, Irvine School of Medicine, Orange, CA.ORCID 0000-0002-9313-3253
Misako NagasakaKarmanos Cancer Institute, Wayne State University, Detroit, MI.ORCID 0000-0001-5308-615X
Robert DoebeleDivision of Medical Oncology, University of Colorado Cancer Center, Aurora, CO.
D Ross CamidgeDivision of Medical Oncology, University of Colorado Cancer Center, Aurora, CO.ORCID 0000-0003-3430-3213
Maria ArcilaMemorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY.
Sai-Hong Ignatius OuChao Family Comprehensive Cancer Center, University of California Irvine Medical Center, Orange, CA.ORCID 0000-0002-1764-4975
Denis Moro-SibilotClinique de Pneumologie, Pôle Médecine Aiguë Communautaire, Centre Hospitalier Universitaire de Grenoble, Grenoble, France.
Rafael RosellCatalan Institute of Oncology, Hospital Germans Trias i Pujol, Badalona, Spain.ORCID 0000-0003-0817-3400
Lucia Anna MuscarellaLaboratory of Oncology, Fondazione IRCCS Casa Sollievo della Sofferenza, Foggia, Italy.
Stephen V LiuLombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC.ORCID 0000-0002-4852-3914
Jacques CadranelDepartment of Pneumology and Thoracic Oncology, Assistance Publique-Hopitaux de Paris, Tenon Hospital and GRC Theranoscan Sorbonne Université, Paris, France.
Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4MNCI NIH HHS P30 CA008748
Abstract
purposeAlthough
methodsFrom June 2018 to February 2020, a consortium of 22 centers from nine countries in Europe, Asia, and the United States contributed data from patients with pathologically confirmed
resultsAlthough the typified never smoking (57%), mucinous adenocarcinoma (57%), and nonmetastatic (71%) phenotype predominated in 110 patients with
conclusion
Indexed as
AdultAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsAsiaBiomarkers, TumorEuropeFemaleFollow-Up StudiesHumansImmunotherapyLung NeoplasmsMaleMiddle AgedNeuregulin-1Oncogene Proteins, FusionBiomarkers, TumorNeuregulin-1NRG1 protein, humanOncogene Proteins, Fusion
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.